TCIM
ADMA icon

TIAA CREF Investment Management’s ADMA Biologics ADMA Stock Holding History

TIAA CREF Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$100K Hold
26,291
– – ﹤0.01% 2963
2018
Q4 		$63K Sell
26,291
-1,085
-4% -$5.37K ﹤0.01% 2987
2018
Q3 		$170K Sell
27,376
-1,635
-6% -$9.42K ﹤0.01% 3010
2018
Q2 		$131K Buy
+29,011
New +$145K ﹤0.01% 3062

Other funds holding ADMA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TIAA CREF Investment Management's ADMA Position: Q1 2019 in Review

TIAA CREF Investment Management held its ADMA Biologics (ADMA) position steady in Q1 2019 at 26,291 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #2963.

TIAA CREF Investment Management first reported a position in ADMA in Q2 2018 and has held it in 4 quarters since. The position peaked at $170K in Q3 2018. 56 funds tracked by Wall St. Rank hold ADMA as of Q1 2019.

  • TIAA CREF Investment Management held 26,291 shares of ADMA Biologics worth $100K as of Q1 2019.
  • TIAA CREF Investment Management left its ADMA Biologics share count unchanged in Q1 2019.
  • ADMA Biologics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2963 holding.
  • TIAA CREF Investment Management first reported a position in ADMA Biologics in Q2 2018 and has held it in 4 quarters since.
  • TIAA CREF Investment Management's ADMA Biologics position peaked at $170K in Q3 2018.
  • 56 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.